Novo Nordisk A/S (NVO)

47.08
NYSE : Health Technology
Prev Close 47.08
Day Low/High 0.00 / 0.00
52 Wk Low/High 37.00 / 58.37
Avg Volume 1.50M
Exchange NYSE
Shares Outstanding 2.01B
Market Cap 116.99B
EPS 2.40
Div & Yield 0.91 (1.94%)

Latest News

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'

Novo Boosts Exploration Team

Novo Boosts Exploration Team

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

Comet Well Tenements Granted

Comet Well Tenements Granted

IIROC Trading Resumption - NVO

IIROC Trading Resumption - NVO

IIROC Trading Halt - NVO

IIROC Trading Halt - NVO

IIROC Trading Resumption - NVO

IIROC Trading Resumption - NVO

IIROC Trading Halt - NVO

IIROC Trading Halt - NVO

"Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support

"Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support

New Findings by Novo Nordisk Provide Insights into Holistic Diabetes Care Management for Patients and Their Physicians

Novo Provides Corporate Update

Novo Provides Corporate Update

TheStreet Quant Rating: B (Buy)